On the other hand, in vivo studies have shown promising results, demonstrating that targeting NAFLD by focusing on ACC and its isoforms could play a crucial role in preventing the progression of the disease to non-alcoholic steatohepatitis [15]. The gene discussed is ACACA; the disease is metabolic dysfunction-associated steatotic liver disease.